In particular, the intranasal treatment with GSK2606414 in DS mice significantly reduced cortical PERK and eIF2α activation, which in turn rescued protein translation demonstrated by in vivo puromycin administration [61]. The gene discussed is EIF2A; the disease is Dravet syndrome.